Frontlight ResearchEarly access
Trial site
American Research Corporation at the Texas Liver Institute
- 10running trials
- 10closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Conditions
- Fatty liver disease (MASLD/MASH)11 trials
- Liver cirrhosis7 trials
- Obesity3 trials
- Primary biliary cholangitis3 trials
- High blood pressure1 trial
- Phase
- Phase 213 trials
- Phase 35 trials
- Phase 12 trials
- Status
- Completed9 trials
- Recruiting7 trials
- Active, not recruiting3 trials
- Terminated1 trial
- Lead sponsor
- Boehringer Ingelheim8 trials
- Ipsen4 trials
- Regeneron Pharmaceuticals3 trials
- Amgen1 trial
- Gilead Sciences1 trial
- and 3 more
Running trials
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Fatty liver disease (MASLD/MASH)5 recruiting
- Liver cirrhosis3 recruiting
- Primary biliary cholangitis1 recruiting
Closed trials
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Completed
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
Site data: ClinicalTrials.govUpdated 19 Nov 2026